• 1
    Stool SE, Berg AO, Berman S, et al. Otitis Media with Effusion in Children. Guideline Technical Report. No 12. AHCPR. Pub No.95-0621. Rockville, MD: US Department of Health and Human Services, 1994.
  • 2
    Zielhuis GA, Rach GH, Broek PV. Screening for otitis media with effusion in preschool children. Lancet 1989;1:31114.
  • 3
    Casselbrant ML, Brostoff LM, Cantekin EI, et al. Otitis media with effusion in preschool children. Laryngoscope 1985;95:42836.
  • 4
    Haggard M, Hughes E. Screening Children's Hearing: A Review of the Literature and Implications of Otitis Media. London, UK: HMSO, 1991.
  • 5
    HES4.DOH. Hospital Episode Statistics. Grommets. (D15). London, UK: Department of Health, 2004. Available from:[Accessed December 16, 2009.
  • 6
    National Institute for Health and Clinical Excellence (NICE). Surgical Management of Otitis Media with Effusion in Children. NICE Clinical Guideline 60. With Costing Report: implementing NICE guidance. London, UK: RCOG Press, 2008.
  • 7
    Butler CC, Van Der Voort JH. Oral Or Topical Nasal Steroids for Hearing Loss Associated with Otitis Media with Effusion in Children. (Cochrane Review) Cochrane Library, Issue 2. Oxford, UK: Update Software, 2002.
  • 8
    Lous J, Burton M, Felding J, et al. Grommets (Ventilation Tubes) for Hearing Loss Associated with Otitis Media with Effusion in Children. Cochrane Library, Issue 1. Chichester, UK: John Wiley & Co, 2005.
  • 9
    Griffin GH, Flynn C, Bailey RE, et al. Antihistamines and/or decongestants for otitis media with effusion (OME) in children. Cochrane Database Syst Rev 2006;(4):Art. No.: CD003423. doi:10.1002/14651858. CD003423.pub2.
  • 10
    Cantekin EI, McGuire TW. Antibiotics are not effective for otitis media with effusion: reanalysis of meta-analysis. Otorhinolarynol Nova 1998;8:21422.
  • 11
    Williamson I, Benge S, Mullee M, et al. Consultations for middle ear disease, antibiotic prescribing and risk factors for re-attendance: a case linked cohort study. BJGP 2006;56:1705.
  • 12
    Tracy JM, Demain JG, Hoffman KM, et al. Intranasal beclomethasone as an adjunct to treatment of chronic middle ear effusion. Ann Allerg Asthma Im 1998;80:198206.
  • 13
    Fokkens WJ, Scadding GK. Perennial rhinitis in the under 4 s: a difficult problem to treat safely and effectively? A comparison of intranasal fluticasone proprionate and ketotifen in the treatment of 2–4 year old children with perennial rhinitis. Pediatr Allergy Immunol 2004;15:2616.
  • 14
    Cengel S, Akyol MU. The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. Int J Ped Otorhinolaryngol 2006;70:63945.
  • 15
    Yaman H, Ozturk K, Uyar Y, et al. Effectiveness of corticosteroids in otitis media with effusion: an experimental study. JLO 2008;122:2530.
  • 16
    Rosenfeld RM, Mandel EM, Bluestone CD. Systemic steroids for otitis media with effusion in children. Arch Otolaryngol Head Neck Surg 1991;117:9849.
  • 17
    Williamson I, Benge S, Barton S, et al. A double-blind randomised placebo controlled trial of topical intra-nasal corticosteroids in 4–11 year old children with persistent bilateral Otitis Media with Effusion in primary care. BMJ 2009; Dec. 16 doi: 10.1136/bmj.b4984 [Epub ahead of print.
  • 18
    Williamson I, Benge S, Barton S, et al. A double-blind randomised placebo controlled trial of topical intra-nasal corticosteroids in 4–11 year old children with persistent bilateral Otitis Media with Effusion in primary care. Health Technol Assess 2009;13:1274.
  • 19
    Timmerman AA, Meesters CM, Anteunis LJ, et al. Psychometric evaluation of the OM8-30 questionnaire in Dutch children with otitis media. Eur Arch Otorhinolaryngol 2008;265:104756.
  • 20
    National Institute for Health and Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal. London, UK: NICE 2007.
  • 21
    Department of Health. NHS Reference Costs 2006. London, UK: Department Health 2006.
  • 22
    Netten A, Curtis L. Unit Costs of Health and Social Care. Canterbury, UK: Personal Social Service Research Unit, University of Kent, 2007.
  • 23
    National Statistics. Prescription cost analysis: England. Available from:[Accessed June 15, 2009.
  • 24
    British Medical Association. British National Formulary. London, UK: British Medical Association, 2007.
  • 25
    Torrance GW, Furlong W, Feeny D, et al. Multi-attribute preference functions: Health Utilities Index. Pharmacoeconomics 1995;7:50320.
  • 26
    Brooks R. EQ-5D, the current state of play. Health Policy 1996;37:5372.
  • 27
    Feeny D, Furlong W, Torrance GW, et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care 2002;40:11328.
  • 28
    Furlong W, Feeny D, Torrance GW, et al. Multiplicative multi-attribute utility function for the Health Utilities Index mark 3 (HUI3) system: a technical report. Centre for Health Economics and Policy Analysis, McMaster University, Canada. Working Paper 98-11, December 1998.
  • 29
    Furlong WJ, Feeny DH, Torrance GW, et al. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001;33:37584.
  • 30
    Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:48796.
  • 31
    Briggs A, Clark T, Wolstenholme J, et al. Missing . . . presumed at random: cost-analysis of incomplete data. Health Econ 2003;12:37792.
  • 32
    Yu LM, Burton A, Rivero-Arias O. Evaluation of software for multiple imputation of semi-continuous data. Stat Methods Med Res 2007;16:24358.
  • 33
    Dakin H, Petrou S, Haggard M, et al. Mapping analyses to estimate health utilities based on responses to the OM8-30 otitis media questionnaire. Qual Life Res 2010;19:6580.
  • 34
    Royston P. Multiple imputation of missing values: update of ice. Stata J 2005;5:52736.
  • 35
    Efron B, Tibshirani R. An Introduction to the Bootstrap. New York, USA: Chapman and Hall, 1993.
  • 36
    Brigg AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess 1999;3:1134.
  • 37
    Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998;S65S80.
  • 38
    Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999;18:34164.
  • 39
    Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:27583.
  • 40
    Van Balen FAM, De Melker RA, Touw-Otten FW. Double blind randomized trial of co-amoxiclav versus placebo for persistent otitis media with effusion in general practice. Lancet 1996;348:71316.
  • 41
    Mendes Leal M, Marques P, Vaz R, et al. Factors in severity of OME seen in secondary care. ESPO, 8th International Conference Proceedings. June 11, 2008. Abstract 5SOP4.
  • 42
    Petrou S. Methodological issues raised by preference-based approaches to measuring the health status of children. Health Econ 2003;12:697702.
  • 43
    Sung L, Petrou S, Ungar W. Measuring health utilities in children and their parents. In: UngarW, ed. Economic Evaluation in Child Health. Oxford, UK: Oxford University Press, 2009.
  • 44
    Eiser C, Morse R. Quality-of-life measures in chronic diseases of childhood. Health Technol Assess 2001;5:1156.